Stocks / NASDAQ / Kintara Therapeutics Inc.

Kintara Therapeutics Inc.

Our Opinion

Kintara Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

Paxalisib is a potent inhibitor of the PI3K pathway, and has been shown to have an anti-tumor effect in animal models of glioblastoma.” Read the following article

Company Description

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.

Company Website: https://www.kintara.com